Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
In a third collaboration with a pharma major within less than a year, US privately-held biotech Skyhawk Therapeutics has entered into a strategic collaboration with Japanese giant Takeda Pharmaceutical. 7 May 2019
Biotechnology
Danish CNS specialist Lundbeck on Monday announced the signing of a definitive agreement into acquire La Jolla, USA-based Abide Therapeutics. 7 May 2019
Biotechnology
US pharma major Eli Lilly has released positive results from pooled subgroup analyses of efficacy data from the Phase III EVOLVE-1 and EVOLVE-2 studies. 7 May 2019
Biotechnology
The US Food and Drug Administration has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin (trastuzumab)-based treatment. 4 May 2019
Biotechnology
An Evidence Report assessing the comparative clinical effectiveness and value of Swiss pharma giant Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS) was released on Thursday by the USA’s Institute for Clinical and Economic Review (ICER). 3 May 2019
Biotechnology
Boosted by a strong sales result from its HIV treatments and from novel cancer med Yescarta (axicabtagene ciloleucel), California’s Gilead Sciences beat analysts’ expectations to take in $5.3 billion in the first quarter of the year. 3 May 2019
Biotechnology
The US Food and Drug Administration has approved Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) for Tibsovo (ivosidenib) for newly-diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation. 3 May 2019
Biotechnology
Shares of Clovis Oncology closed up 4.12% at $18.44 yesterday, after the US biotech firm revealed an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis’ costs and expenses related to the ATHENA clinical trial. 3 May 2019
Biotechnology
Cambridge, UK-based AstraZeneca has been granted approval to market its once-daily SGLT-2 inhibitor Qternmet XR (dapagliflozin/saxagliptin/metformin hydrochloride) in the USA. 3 May 2019
Biotechnology
East Coast, USA-based biotech BioXcel Therapeutics says it has finalized formulation development for its candidate BXCL501, with the aim of supporting a Phase III trial later in the year. 3 May 2019
Biotechnology
Geneva, Switzerland-based biotech Amal Therapeutics has entered into a collaborative agreement with German family-owned pharma major Boehringer Ingelheim. 2 May 2019
Biotechnology
Thankfully, the growing anti-microbial resistance (AMR) crisis is now getting some major headlines and airtime, so that even many lay people are getting a good grasp of the issues at the heart of this global priority. 2 May 2019
Biotechnology
US biotech firm bluebird bio has appointed Joanne Smith-Farrell to chief business officer. In this role, she will lead corporate development and strategy, and she will also continue to serve as our oncology franchise leader. 2 May 2019
Biotechnology
Antibiotics specialist Nabriva Therapeutics has been hit by a Complete Response Letter (CRL) from the US regulator, sending its share price down by almost a third. 2 May 2019
Biotechnology
Strasbourg, France-based biotech firm Transgene has entered into a research, option and license deal with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. 2 May 2019
Biotechnology
UK-based AstraZeneca has entered into a collaboration with BenevolentAI to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). 1 May 2019
Biotechnology
Amgen late yesterday announced financial results for the first quarter of 2019, noting that total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018, largely in line with consensus analysts’ estimates of $5.55 billion. 1 May 2019
Biotechnology
Hot on the heels of approvals in North America and Japan, Skyrizi (risankizumab) has been approved by the European Commission for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 30 April 2019
Biotechnology
Swedish Orphan Biovitrum, the Nordic biotech company known as Sobi, has appointed Amy Pott as the new head of Sobi North America. She takes over effective today, replacing Rami Levin who is leaving Sobi. 30 April 2019
Biotechnology
In the perennial search for blockbusters, US drugmaker Regeneron has agreed exclusive rights to access the technology and expertise of Calixar to conduct research and discovery of antibodies against an undisclosed target in various therapeutic fields. 29 April 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze